Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.

Che C ColpittsRajiv G TawarLaurent MaillyChristine ThumannLaura HeydmannSarah C DurandFei XiaoEric RobinetPatrick PessauxMirjam B ZeiselThomas F Baumert

Published in: Gut (2017)

Overall, these findings underscore the clinical potential of CLDN1-targeted therapies and describe the functional characterisation of a humanised anti-CLDN1 antibody suitable for further clinical development to complement existing therapeutic strategies for HCV.

Keyphrases

monoclonal antibody
hepatitis c virus
risk assessment
climate change
antiretroviral therapy